



Latest Alirocumab Data in Focus



We are pleased to invite you to view a webinar broadcast on select alirocumab data presented at the 2020 American College of Cardiology (ACC) together with the World Congress of Cardiology (WCC) Scientific Sessions (ACC.20/WCC).

You will be able to register for one of the following two time slots:



Thursday 4 June,
13:00–14:30 Central European Time

Thursday 4 June,
20:00–21:30 Central European Time

[Sign up](#)

[Sign up](#)

*By clicking on the above links, you are acknowledging that you have read and understood the terms and conditions outlined at the bottom of this invitation.

On **Thursday 4 June**, a webinar delivering select scientific data for alirocumab will be presented by nominated authors, including **Professor J Wouter Jukema** (The Netherlands), **Professor Michal Vrablik** (Czech Republic) and **Professor Maciej Banach** (Poland). The focus of this presentation will be to review recently released alirocumab analyses abstracts presented at ACC.20/WCC; two based on ODYSSEY OUTCOMES data and one based upon alirocumab use in a real-life setting. This webinar will also examine ODYSSEY OUTCOMES data, with consideration for other CVOTs.

On **Thursday 4 June, 13:00–14:30 Central European Time (session one) and 20:00–21:30 Central European Time (session two)**, the following abstracts will be discussed, followed by time for an interactive Q&A:

- **Introduction to the webinar: Welcome, objectives and recognising the current global COVID-19 health situation**
- **ODYSSEY OUTCOMES – Background and timeline: A review of the study design, topline results and a timeline overview of sub-analyses readouts**
- **Select most recent ODYSSEY OUTCOMES sub-analyses**
 - **ACC presentation: ODYSSEY OUTCOMES achieved LDL-C based on EU guidelines**
 - **ACC presentation: ODYSSEY OUTCOMES revascularisation**
 - **Panel discussion on the results and key points on urgency to treat/early treatment with PCSK9 inhibitors in general, according to recommendations in the EU guidelines**
- **ODYSSEY OUTCOMES in perspective of other CVOTs**
 - **Panel discussion on evaluation of CVOTs to date and key critical findings informing disease management**
- **Real-world experience with PCSK9 inhibitors: ODYSSEY APPRISE and available inhibitor registry data**
 - **Panel discussion on the real-world use of PCSK9 inhibitors**
- **Interactive Q&A with the panel**
- **Closing remarks**

Timings for Thursday 4 June

Session 1


07:00–08:30 Eastern Daylight Time
13:00–14:30 Central European Time
16:00–17:30 Dubai Standard Time
19:00–20:30 China Standard Time
20:00–21:30 Japan Standard Time

Session 2

14:00–15:30 Eastern Daylight Time
20:00–21:30 Central European Time
23:00–24:30 Dubai Standard Time
02:00–03:30 China Standard Time
03:00–04:30 Japan Standard Time

If you cannot join the webinar live, please feel free to sign up and let us know if you would like to receive a recording of the webinar – you will be able to do this on the registration page.

We hope that you will be able to join us and look forward to your participation.



54, Rue La Boétie,
75008 PARIS - France

©2002-2020 Sanofi-Aventis Groupe.
All rights reserved.

Legal Statement

Alirocumab is co-developed by Sanofi and Regeneron. Sanofi and Regeneron do not recommend the use of any product outside of their approved indications. Please consult your local prescribing information before prescribing. Alirocumab is not available in all countries. Please check with your local regulatory agencies for more details.

MAT-GL-2000107. Date of approval: April 2020

Please DO NOT REPLY TO THIS MESSAGE.

To be removed from our mailing list, [please click here](#)

PRIVACY POLICY

SANOFI commits to protect your personal data and your privacy and implements all necessary means to ensure such protection, in accordance with its Global Privacy Policy. This Privacy Notice will explain to you the purpose and the modalities by which SANOFI processes your personal data through this mobile application.

The personal data collected through this form is processed under the control of Sanofi-Aventis Groupe, 54 rue de la Boétie 75008 Paris, +33153774000.

For any queries concerning the processing of your Personal Data, you can contact SANOFI's Data Protection Officer at this address: privacy-office-global@SANOFI.com

Unless stated otherwise, the communication of your personal data to SANOFI and the processing by SANOFI is mandatory to benefit of Sanofi medical webinars services. Should you refuse to communicate your data, SANOFI may not be able to grant you access to the services.

In the context of this processing, SANOFI may process the following types and categories of personal data relating to you: identification and contact information, professional information (notably training, education, specialty, professional interests, etc.), personal preferences relating to the receipt of professional communications, browsing and other activity related to websites, applications and communications received from SANOFI, details of your interactions with SANOFI (frequency, interaction methods, topics discussed, etc.).

Your personal data will be used by SANOFI to analyse and predict your preferences and professional interests, with a view to offer you customised or individualised medical and commercial information and content on the medical environment, stock outs, or services and/or products of SANOFI. It will also be used to adjust the types of communications (format, content) we send to you as well as to adjust the communication channels used to send you our communications. This processing uses an automated decision-making system to enable Sanofi to profile your use of our products, services and communication.

Your personal data will also be used (both in aggregated or identified format) to allow us to improve our products and services, notably the effectiveness of our communications, the quality and pertinence of our products and services or provide useful tips, information and insights to other users of our products and services. Your data may also be used, once anonymised, for analytical, statistical purposes.

SANOFI is a multinational Group. In this context, SANOFI may need to transfer your data towards entities of its Group. SANOFI may also need to share your personal data with third party partners outside of the SANOFI Group to process your data. Such SANOFI or non-SANOFI entities may be located outside the Economic European Area, in countries where the legislation does not necessarily offer the same level of data protection, or in countries not recognised by the European Commission as offering an adequate level of protection.

In order to ensure an adequate level of protection of your data, those transfers are safeguarded by SANOFI in accordance with the requirement of European law, notably the Sanofi Binding Corporate Rules and the European Standard Contractual Clauses.

SANOFI may also need to communicate your data to judicial and administrative authorities in accordance with legal or regulatory requirements and/or to respond to specific requests or orders in the framework of judicial or administrative procedures.

In accordance with the rights granted to you by law, you are entitled to:

- access by simple request to your personal data – in which case you may request to receive a copy of your personal data, unless such personal data is made available to you directly;
- to request a rectification of your personal data if such is inaccurate, incomplete or obsolete;
- to obtain the deletion of your personal data in the specific cases provided for by law;
- to obtain a limitation of the processing of your data in the specific cases provided for by law;

Should a difficulty arise, you can send an information request directly to our Data Protection Officer at the following address: <https://www.sanofi.com/en/our-responsibility/sanofi-global-privacy-policy/contact>. You can also lodge a complaint with the COMMISSION NATIONALE DE L'INFORMATIQUE ET DES LIBETÉS.

SANOFI retains your personal data until it is aware that you have left your job as a health professional, and as long as you do not withdraw your consent for the processing of such personal data. In any case, your personal data will be deleted or anonymised after 3 years without contact from you (request for information, authentication on a SANOFI site, etc.).